Return On Asset ratio Analysis of Zynerba Pharmaceuticals Inc - Deep Dive
Latest FY ROA
Period Ending - Dec-22
Very Poor ROA
-63.10
Period Ending - Dec-21
Very Poor ROA
-45.96
Growth
-37.29 %
Trailing Twelve Months ROA
Period Ending - Dec-22
Very Poor ROA
-101.40
Most recent Quarter ROA
Period Ending - Jun-23
Very Poor ROA
-26.62
ROA Analysis of Zynerba Pharmaceuticals Inc
ROA Ratio of Zynerba Pharmaceuticals Inc with value of -101.40 means poor return on Assets in trailing twelve months. |
ROA Ratio of Zynerba Pharmaceuticals Inc with value of -26.62 means poor return on Assets in latest Quarter ending on Jun-23. |
ROA Ratio of ZYNE drastically fell by -37.29 % this year. |
ROA Ratio with value of -37.54 was highest in Year Dec-19 in last Five Years. |
ROA Ratio with value of -69.32 was lowest in Year Dec-20 in last Five Years. |
Latest ROA Ratio with value of -63.10 is lower than Average ROA of -55.04 in last five years. |
ROA of Zynerba Pharmaceuticals Inc is negative because of negative Income in last Financial Year , last Quarter and also in last twelve Months. |
Other ROA Related Info of ZYNE that may interest you.
Zynerba Pharmaceuticals Inc Overview
Code | Price | Previous Price | Price Change | Sector |
---|---|---|---|---|
ZYNE | 1.3 | 1.27 | 2.36 % | Drug Manufacturers-Specialty & Generic |
Defination of Return On Asset
The return on assets (ROA) is a commonly used profitability ratio that shows how effectively a company uses its assets to generate profit. more ..ROA Related Ratios
ReturnOnEquity | AssetTurnoverRatio |
Tsr Profitability Index
Poor Profitability Stock |
FY - Historical Return On Asset of Zynerba Pharmaceuticals Inc
Period | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
---|---|---|---|---|---|---|---|
ROA | -63.10 | -45.96 | -69.32 | -37.54 | -59.28 | -46.36 | -63.98 |
Change | -37.29 % | 33.70 % | -84.68 % | 36.68 % | -27.87 % | 27.55 % | -122.48 % |
FY Chart of Return On Asset of Zynerba Pharmaceuticals Inc
Note : All Data Generated at the End of Trading Hours (EOD Data)